Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of hetrombopag olamine for chemotherapy-induced thrombocytopenia
ChiCTR2200057752Phase 2Not yet recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of hetrombopag in chemotherapy-induced thrombocytopenia (CIT), sponsored by Zhejiang Cancer Hospital. Primary endpoint: Time to platelet recovery to >=100×10^9/L from nadir during treatment phase. Planned start Mar 2022; status: not yet recruiting.
02
Drugs
hetrombopag
03
Conditions
chemotherapy-induced thrombocytopenia (CIT)
Beyond the preview
Go deeper on ChiCTR2200057752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200057752.